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Inflammation in HIV infection is predictive of non-AIDS morbidity and death 1 , higher set point plasma virus load 2 and virus acquisition 3 ; thus, therapeutic agents are in development to reduce its causes and consequences. However, inflammation may simultaneously confer both detrimental and beneficial effects. This dichotomy is particularly applicable to type I interferons (IFN-I) which, while contributing to innate control of infection [4] [5] [6] [7] [8] [9] [10] , also provide target cells for the virus during acute infection, impair CD4 T-cell recovery, and are associated with disease progression 6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] . Here we manipulated IFN-I signalling in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to AIDS despite decreased T-cell activation. In contrast, IFN-a2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-a2a treatment induced IFN-I desensitization and decreased antiviral gene expression, enabling infection with increased SIV reservoir size and accelerated CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation. Yet, the clinical consequences of manipulation of IFN signalling are difficult to predict in vivo and therapeutic interventions in human studies should be approached with caution.
We designed and produced an IFN-I receptor antagonist (IFN-1ant) that blocks IFN-a2 antiviral and antiproliferative activity in vitro 19 . Six rhesus macaques received 1 mg of IFN-1ant daily for 4 weeks following intrarectal challenge with SIV MAC251 (dosage based on previous doseresponse studies; Extended Data Fig. 1a-d) ; nine macaques received saline (Extended Data Fig. 1e ). Initial assessment of in vivo effects revealed delayed peak mRNA expression of MX1 and OAS2 in the IFN-1ant macaques (Extended Data Fig. 2a, b ), but peak expression levels did not differ between cohorts. Whole-transcriptome sequencing revealed that expression of most interferon-stimulated genes (ISGs) in peripheral blood mononuclear cells (PBMCs) was significantly decreased at 7 days post-infection (d.p.i.) in the IFN-1ant-treated compared to placebo-treated macaques (Fig. 1a) , including the antiviral genes APOBEC3G and MX2, those that code for cyclic GMP-AMP synthase (cGAS) and tetherin 4, 5, 20 , and IRF7, a master IFN-I signalling inducer 21 , indicating profound disruption of IFN-I signalling ( (Fig. 1c) . Thus, IFN-1ant treatment during acute SIV infection resulted in delayed and decreased antiviral gene and protein expression in peripheral blood and lymph nodes.
Consistent with reduced antiviral gene expression, IFN-1ant macaques had significantly higher plasma viral loads (pVLs) than placebo macaques during acute infection ( Delayed peak ISG expression, however, was predictive of higher pVLs at peak and 12 w.p.i. and higher PBMC-associated SIV gag DNA levels at 28 d.p.i. (Extended Data Fig. 2f-h) . Additionally, the number of lymph node SIV RNA 1 cells per mm 2 as determined by in situ hybridization was significantly higher in macaques treated with IFN-1ant compared to placebo during chronic infection (Fig. 2b) . Thus, early IFN-I signalling was critical for early and long-term control of SIV replication and virus reservoir size.
Although both groups experienced a similar, significant decrease in circulating CD4 T-cell frequency ( Fig. 2c ) and CD4/CD8 T-cell ratio (Extended Data Fig. 3a ) between 0 and 12 w.p.i., IFN-1ant macaques experienced a profound decline with a lower lymph node CD4 T-cell frequency and CD4/CD8 T-cell ratio beyond 12 w.p.i. (Fig. 2d and Extended Data Fig. 3b ). The frequency of CCR5 1 memory CD4 T cells, potential targets for infection, was significantly lower in blood in IFN-1ant-treated than placebo-treated rhesus macaques through 12 w.p.i. (Fig. 2e) , and lymph nodes at 4 and .12 w.p.i. (Fig. 2f ), suggesting depletion due to infection. Circulating T-cell activation, reflected by HLA-DR 1 and Ki67 1 memory CD4 and CD8 T-cell frequencies, was not significantly different between groups at 4 or .12 w.p.i. (Supplementary Information). However, HLA-DR 1 and Ki67 1 memory CD4 and CD8 T-cell frequencies were significantly lower in the lymph nodes of IFN-1ant macaques than placebo at .12 w.p.i. (Extended Data Fig. 3c-f ). Taken together, IFN-I signalling blockade during acute SIV infection resulted in attenuated T-cell activation in lymphoid tissue yet accelerated CD4 T-cell depletion.
Clinical outcome ultimately gives the most comprehensive measure of disease state. Consistent with a median life expectancy of 1 year 22 , the six placebo-treated macaques followed through 44 w.p.i. (three were transferred to another study before 30 w.p.i.) lived, but the IFN-1ant macaques began dying of AIDS at 24 w.p.i. and all were euthanized per protocol for signs of AIDS by 30 w.p.i. (Fig. 2g) . Thus, blocking IFN-I signalling during only the first 4 weeks of infection resulted in accelerated disease progression and death from AIDS.
Exploration of the molecular mechanisms underlying the accelerated disease progression by whole-transcriptome sequencing revealed statistically significant enrichment of pathways regulating innate immunity, IFN-I production and T-and B-lymphocyte activation (Extended Data Fig.  4a -c) with significant downregulation of most genes in the IFN-1ant group at 7 d.p.i. compared to placebo-treated controls ( Fig. 1d and Extended Data Fig. 2c ). Relative to placebo, the most significantly perturbed pathway in the IFN-1ant-treated animals consisted of pathogen-associated pattern recognition receptor (PRR) signalling molecules ( Fig. 1d and Extended Data Fig. 4a) , with significant downregulation of several viral PRRs (TLR3, TLR7, DDX58/RIG-I, MDA5/IFIH1) and their downstream adaptors (TICAM1/TRIF) or transcription factors (IRF7) in IFN-1ant macaques compared to placebo (Extended Data Fig. 4c ). Concordantly, expression of the downstream mediators IL-6, TNF and IL-1b was significantly reduced.
Consistent with their responsiveness to , the frequencies of total and cytotoxic CD16 1 natural killer (NK) cells were significantly lower in the IFN-1ant group than placebo at .12 w.p.i., although there were no diferences at 4 w.p.i. (Extended Data Fig. 3g-i) . However, we observed no significant differences in phenotype, function or timing of CD4 or CD8 T-cell responses (Extended Data Fig. 5 and Supplementary Information).
Collectively, these data suggest that IFN-I signalling early in SIV infection is critical for innate immune control of virus replication and that its antagonism, even if only brief during the acute phase, results in decreased virus control, accelerated CD4 T-cell depletion and progression to AIDS.
Given these findings, we hypothesized that administering IFN-I could improve SIV MAC251 control despite evidence suggesting that inflammation exacerbates virus acquisition and disease progression [1] [2] [3] 13 . Six macaques received 6 mg kg 21 pegylated IFN-a2a dosed weekly, as determined in prior studies 24 , starting 1 week before challenge and continued through 4 weeks after systemic infection (defined as detectable pVL 7 days postchallenge). Macaques were followed until 12 w.p.i. then euthanized per protocol (Extended Data Fig. 1e ). Whereas all nine placebo macaques were infected after the first intrarectal inoculation, IFN-a2a treatment significantly delayed systemic infection, necessitating two, three or five challenges to infect these macaques (Fig. 3a) , and significantly decreased the number of transmitted/founder variants (Extended Data Fig. 8a ). The macaques that required more challenges had fewer transmitted/founder variants (Fig. 3b) ; however, the circulating viruses at peak viral load in both groups were equally susceptible to in vitro IFNa inhibition (data not shown). Thus, treatment with IFN-a2a during SIV challenge increased host resistance to systemic infection.
We assessed whether ISGs may have contributed to resistance to infection. We found that MX1 and OAS2 gene expression detected by quantitative reverse transcription PCR (qRT-PCR) increased after one IFN-a2a dose but decreased after repeated administration, suggesting an IFNdesensitized state (Extended Data Fig. 6a-d ) resulting in no significant differences between treated and placebo groups on the day of infectious challenge. Furthermore, IFN-a2a macaques had lower ISG expression compared to placebo at 7 and 10 d.p.i., including those encoding cGAS, APOBEC3G, MX2 and tetherin (Fig. 3c-f and Extended Data Fig. 7a-b) . At 4 w.p.i., after 6, 7 or 9 doses of IFN-a2a, lymph node TRIM5a protein expression was significantly lower in the IFN-a2a group compared to placebo (Extended Data Fig. 8b ). To explore the effects of IFN-a2a administration on ISG expression further, we performed whole-transcriptome sequencing on uninfected rhesus macaques administered pegylated IFNa2a for 3 weeks. Seven days after one IFN-a2a dose, expression of virus restriction factors including TRIM22, MX2 and IRF7 was increased in PBMCs, lymph nodes and rectum (Extended Data Fig. 7c-h ). However, after 3 doses these ISGs returned to pre-treatment expression levels (MX2) or lower (TRIM22 and IRF7), consistent with the timing of infection of the SIV-challenged macaques. (Extended Data Fig. 7c-h ). We found no in vitro IFN-neutralizing activity in the plasma at the time of infection to explain the loss of exogenous IFN-a2a activity (Extended Data Fig. 6e and Supplementary Information), suggesting that ISG downregulation probably occurred as a result of intrinsic regulatory mechanisms. Indeed, FOXO3a, a central regulator of IFN-I feedback 25 , was significantly upregulated in the IFN-a2a compared to placebo macaques at 7 d.p.i. (Fig. 3g and Extended Data Fig. 6g ) and, concordantly, ISGs demonstrated to be repressibly bound by FOXO3a (ref. 25) had lower expression at 7 d.p.i. (Extended Data Fig. 6h) . We also assessed a broad panel of genes predicted to be bound by FOXO3a (ref. 25 ) using gene-set enrichment analysis and observed a significantly lower cumulative ranking of FOXO3a targets in the 7 d.p.i. IFN-a2a-treated macaque transcriptome data when contrasted to the 7 d.p.i. placebo data (Fig. 3h) , suggesting increased FOXO3a-mediated repression in the IFN-a2a macaques. Indeed, after 21 days of 
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IFN-a2a treatment in the unchallenged macaques, increased FOXO3a expression was associated with ISG downregulation (Extended Data  Fig. 6f ). While these data do not exclude additional mechanisms, they suggest that ISG downregulation in the IFN-a2a-treated macaques was a consequence of endogenous homeostatic control rather than neutralization of exogenous IFN-a2a. Thus, exogenous augmentation of IFN-I signalling was associated with enhanced protection against SIV acquisition, but susceptibility to exacerbated systemic infection once ISG expression waned.
Given their roles in virus control, T and NK cells were evaluated. No changes in SIV-specific CD4 or CD8 T-cell responses developed with repeated challenges, suggesting that resistance to infection did not depend on adequate T-cell responses (Supplementary Information). However, higher circulating CD56
1 NK-cell frequencies after starting IFN-a2a predicted more challenges necessary for infection and were associated with resistance to infection (Extended Data Fig. 8c ). Once the CD56
1 NK-cell 
i.). f, Frequency of CCR5
1 memory CD4 T cells in lymph nodes in macaques treated with IFN-1ant (n 5 6) or placebo saline (n 5 9). Horizontal bars represent median values. P values at different time points within treatment groups were calculated by Wilcoxon matched pairs signed rank test and between groups by Mann-Whitney U test. g, Kaplan-Meier survival curve comparing macaques treated with IFN-1ant (n 5 6) to macaques that received placebo (n 5 9). P value indicates the significance by logrank (Mantel-Cox) test for survival by 32 w.p.i. For all panels, IFN-1ant-treated macaques are represented in red, placebo-treated macaques in blue. . The line plot indicates the running-sum of the enrichment score; the leading edge is indicated in magenta. The relative positions of all genes within the ranked data set are shown in the stick plot below the x axis. P value indicates statistical significance of the enrichment score, reflecting lower cumulative ranking of FOXO3a targets in IFN-a2a-treated macaques compared to placebo at 7 d.p.i. For all panels, IFN-a2a-treated macaques are represented in green, placebo-treated macaques in blue.
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frequency declined, the macaques became infected. In rectal biopsies at 28 d.p.i., more resistant macaques had higher CD16 1 NK-cell frequencies (Extended Data Fig. 8d ). Together, these data suggest that IFN-a2a-induced innate immunity, rather than T-cell responses, protected against SIV infection.
Despite fewer transmitted/founder variants, pVLs did not differ significantly between IFN-a2a and placebo groups (Extended Data Fig. 8e) , potentially obscured by the variability and small number of macaques. PBMCassociated SIV gag DNA levels, however, were significantly higher in the IFN-a2a group than placebo at 10, 14 and 28 d.p.i. (Fig. 4a) . While the circulating CD4 T-cell frequency (Fig. 4c ) and CD4/CD8 T-cell ratio (Fig. 4d ) declined between 0 and 4 w.p.i. in both groups, the CD4/CD8 T-cell ratio was significantly lower in the IFN-a2a group (based on area under the curve (AUC) (0-12 w.p.i.)). The CCR5 1 memory CD4 T-cell frequency in blood was significantly lower in IFN-a2a than placebo macaques during acute (AUC(0-4 w.p.i.), Fig. 4e ) and chronic infection (AUC(0-12 w.p.i.)) and in lymph nodes at 4 ( Fig. 4f ) and 12 w.p.i., although the frequency of CD4 T cells and CD4/CD8 T-cell ratio in lymph nodes and jejunum were similar between groups at 4 and $12 w.p.i. (data not shown). Thus, SIV-infected IFN-a2a-treated macaques had increased CD4 T-cell-associated virus load and greater CD4 T-cell loss with preferential depletion of the CCR5 1 subset. We assessed whether increased immune activation was associated with this CD4 T-cell loss. The circulating Ki67
1 memory CD4 and CD8 T-cell frequencies were lower in the IFN-a2a compared to placebo group during acute infection only (AUC(0-4 w.p.i.)) with no differences in the frequencies of HLA-DR 1 memory T cells (Extended Data Fig. 9a-d ). In the lymph nodes, the frequencies of Ki67 1 memory CD4 T cells at 4 w.p.i. and HLA-DR 1 memory CD4 T cells at $12 w.p.i. were significantly lower in the IFN-a2a than placebo group with no differences in CD8 T cells (Extended Data Fig. 9e-h) . Thus, the IFN-a2a macaques had similar or less immune activation compared to placebo macaques.
We further explored the mechanisms underlying the increased cellassociated SIV and CD4 T-cell depletion in IFN-a2a macaques using whole-transcriptome sequencing of PBMCs. As with IFN-1ant, IFNa2a administration significantly affected the PRR signalling pathway (Extended Data Fig. 10a) . C1q, TLR3, TLR7 and RIG-I were downregulated in the IFN-a2a macaques, yet expression of IL-6, TNF and IL-1b was increased at 7 d.p.i. (Fig. 4b and Extended Data Fig. 10b ). Mediators of stress responses and cell survival downstream of IL-6 signalling, such as MAP2K3, and other anti-apoptotic genes such as DIABLO and BCL2L1 were upregulated at 7 d.p.i. (Extended Data Fig. 10b, 10c ), whereas pro-apoptotic genes including CASP10 were downregulated. Thus, early IFN-a2a administration increased early expression of proinflammatory cytokines despite decreased PRR expression and delayed induction of apoptotic pathways.
We next assessed T-and NK-cell-mediated immunity. IFN-a2a-treated macaques had intact and even enhanced SIV-specific CD8 T-cell responses with no deficits in CD4 T-cell responses (Extended Data Fig. 8f-i and Supplementary Information). Whereas there were no differences at 4 w.p.i., between 4 and 12 w.p.i., the CD56 1 NK-cell frequency increased and CD16
1 NK-cell frequency decreased in the IFN-a2a but not the placebo group. The frequencies of CD16 1 (Extended Data Fig. 8j ), CD107a 1 and granzyme B
1 NK cells at 12 w.p.i. were subsequently lower in the IFNa2a-treated macaques compared to placebo.
Taken together, these data show that despite initially increasing ISG expression and conferring resistance to SIV infection, continued IFN-a2a treatment resulted in an IFN-desensitized state, with decreased antiviral gene expression, increased susceptibility to infection, increased cell-associated virus load and greater CD4 T-cell depletion compared to placebo.
Thus, both IFN-I receptor blockade and IFN-a2a administration ultimately resulted in decreased and delayed IFN-I responses, the biological outcomes of which reveal a pivotal role for IFN-I signalling in acute retroviral exposure in primates that overshadows the potential harm of increased inflammation. That a delay of as few as 3 days in antiviral gene expression resulted in accelerated disease progression suggests that SIV disease course is determined very early and depends upon the precise timing of peak antiviral activity. The observation of shortened time-to-death despite the eventual normalization of ISG expression during chronic infection clearly shows that a resurgence of late antiviral activity cannot compensate for compromised early virus control. Indeed, administration of IFN-a in chronic HIV infection has given inconsistent results for virus load and CD4 T-cell counts with no effect on disease outcome [7] [8] [9] . An interesting parallel to our study was recently described in mice with chronic lymphocytic choriomeningitis virus infection where persistent IFN-I signalling exerts antiviral effects but also leads to immune hyperactivation and suppression of antiviral 
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T-cell responses 14, 15 . Our findings differ from a previous study that reported unchanged virus burden with IFN-a2a administration during chronic SIV infection 24 and a study of IFN-a2b or the IFN-aB/D chimaera in rhesus macaques challenged intravenously with highly pathogenic SIV Delta B670 that showed no protection from infection but decreased peak antigenaemia 26 . The initial protection from infection and decrease in transmitted/founder variants observed in our study highlight the rectal mucosa's function as a barrier to SIV during transmission in the context of ISG induction. It is tempting to speculate that administration of IFN-a2a before SIV challenge also facilitated NK-cell activation and recruitment to the rectum and contributed to protection from infection 27 . Given the relative IFN-I resistance of transmitted/founder viruses 28, 29 and the induction of an IFN-desensitized state associated with the upregulation of the IFN-I pathway repressor FOXO3a (ref. 25) , our findings add a cautionary note to adjuvanted HIV vaccines or other prevention approaches that induce ISGs at mucosal surfaces. Furthermore, while the rectum contains many resident target CD4 T cells 30 that antiviral mediators can protect, sites with few resident target cells, such as the female genital tract 16 , may depend on IFN-I signalling for CD4 T-cell recruitment and virus propagation. Thus, inflammation might attenuate transmission at the former site but exacerbate it at the latter 3 . In conclusion, disease progression in HIV infection emerges from the balance between the beneficial antiviral effects of inflammation, its detrimental systemic and immunologic effects, and its unique role of providing activated CD4 T-cell targets for HIV. Interfering with one part of this unstable equilibrium has unpredictable consequences. Thus, while there is good reason to use both pro-and anti-inflammatory therapeutic approaches in the treatment and prevention of HIV infection, they should be embarked upon with careful assessment of the virological and immunological consequences before widespread implementation.
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Dose escalation study. We performed a dose escalation study in two rhesus macaques with chronic SIV MAC251 infection and different frequencies of CD4 T cells and CCR5 1 CD4 and CD8 T cells to maximize the likelihood of detecting a response. IFN-1ant was dosed three times a week based on dosing of recombinant IFN-a2a (Roferon-A, Roche, Switzerland) for hepatitis C infection. We administered 50 mg of IFN-1ant for one week, 200 mg for one week, 500 mg for one week and 800 mg for one week. Based on a dose-dependent increase in CD4 T-cell frequency and decrease in the frequencies of CCR5 1 CD4 and CCR5 1 and Ki67 1 CD8 T cells (Extended Data Fig. 1a-d) , and because of ease of administration, we decided on 1 mg of IFN-1ant. Daily dosing was chosen as the effects appeared to be variable based on the time since last dosing. Macaques and experimental design. To examine the effects of blocking type I IFN signalling, healthy, SIV-uninfected Mamu A01
B17
2 adult Macaca mulatta received 1 mg daily intramuscularly of the IFN-I receptor antagonist (IFN-1ant, 1 mg ml 21 , n 5 6; synthesized as previously described 19 ) or 1 ml normal saline (n 5 9) by intramuscular injection for 4 weeks (see Extended Data Fig. 1e ). The macaques were inoculated weekly, starting the first day of treatment, with 1 ml of SIV MAC251 via rectal challenge (1 ml of a 1:25 dilution, stock 3 3 10 8 SIV RNA copies ml
21
), up to three times until infection was confirmed (SIV pVL .250 copies ml
). Blood was sampled several times per week, and lymph node and jejunal biopsies were performed before treatment and at the end of the 4-week period. All blood draws and biopsies were performed before inoculation with SIV MAC251 and before any drug administration on that day. The macaques were followed for up to 40 w.p.i.
To examine the effect of exogenous IFN-I treatment, six healthy, SIV-uninfected Mamu A01
2

B08
2
B17
2 adult macaques received 6 mg kg 21 pegylated IFN-a2a (Pegasys, Genentech USA) intramuscularly weekly starting one week before the first SIV MAC251 inoculation. Dose was based on prior efficacy studies in rhesus macaques 24 . The macaques were challenged intrarectally weekly on the same day as, but before, IFN-a2a administration, with the same high-dose SIV MAC251 inoculation as the IFN1ant and placebo macaques, until infection was confirmed. All blood draws and biopsies were performed before inoculation with SIV MAC251 and before any drug administration on that day. The macaques were followed for a total of 12 weeks after infection and then euthanized per protocol. To examine the effect of exogenous IFN-I treatment in the absence of SIV infection, three healthy, SIV-uninfected Mamu A01
2
B08
2
B17
2 adult macaques received 6 mg kg 21 pegylated IFN-a2a (Pegasys, Genentech USA) intramuscularly weekly for 3 weeks. Blood was sampled twice weekly starting 1 week before IFN-a2a treatment through to 1 week after the last dose. The lymph node, jejunum and rectum were biopsied before IFN-a2a treatment, 1 week after the first dose and 1 week after the last dose.
All macaques were housed at Bioqual, Inc., and assigned randomly to treatment or placebo arms. TRIMCyp, the fusion protein derived from TRIM5 and cyclophilin A, was present in 1 placebo macaque, 2 IFN-1ant macaques and 0 IFN-a2a macaques. One TRIM5a SPRY deletion was present in 4 placebo macaques, 3 IFN1ant macaques and 1 IFN-a2a macaque (the macaque that required 5 challenges to become systemically infected) and two TRIM5a SPRY deletions in 2 IFN-1ant macaques. There was no significant difference in genotype distribution between placebo and IFN-1ant macaques or between placebo and IFN-a2a macaques based on Fisher's test. Based on availability, the 6 IFN-1ant macaques and 9 placebo macaques were male and ages 4 to 7 years, and the 6 IFN-a2a macaques were female with ages 9 to 15 years. The Vaccine Research Center Animal Care and Use Committee approved all study protocols and procedures. Samples. Blood was collected in EDTA tubes. Plasma was collected and PBMCs were isolated by Ficoll density centrifugation. All of the jejunum and half the lymph node biopsy tissues and half of every tissue collected at necropsy were placed in RPMI with 10% fetal bovine serum (FBS) and transported on wet ice. The remaining tissues were placed in 4% paraformaldehyde and kept at room temperature overnight before being transferred to 80% ethanol and stored at 4 uC. Tissues were subsequently paraffin-embedded for in situ hybridization and immunohistochemistry. Intestinal samples were incubated with RPMI 1 collagenase D (1 mg ml 21 ) (Roche) 1 Penicillin-Streptomycin-Glutamine (Gibco) at 37 uC for 30 min and then passed through a 70 mm filter. Lymph node samples were passed through a 70 mm filter to remove debris. Cells isolated from both peripheral blood and tissues were either stained for flow cytometry or cryopreserved. Flow cytometry. Cellular activation and cell cycle entry were assessed by flow cytometry. PBMCs and cells from the jejunum and lymph nodes were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain and antibodies to the following: CD4 Qd605, CD8 Qd655 (Invitrogen); CD3 APC-Cy7, CD95 PE-Cy5, CD14 Pacific Blue, CCR5 PE, CCR7 PE-Cy7, Ki67 FITC (BD Biosciences); CD28 ECD (Beckman Coulter); and HLA-DR Alexa 700PE (BD Biosciences, in-house conjugate). Cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) for Ki67 detection and fixed with 1% formaldehyde (Tousimis).
To assess antigen-specific responses and NK cell subsets, cryopreserved PBMCs were stimulated for 6 h at 37 uC with SIV Gag/Env/Pol peptide pool (2 mg ml 21 ) in the presence of CD28 and CD49d (BD Biosciences) and brefeldin A (Sigma, 10 mg ml
21
). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain (Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD14 Pacific Blue, IFN-c Cy7PE, TNF APC, CD107a FITC (BD Biosciences); Granzyme B PE (Caltag); CD4 Qd605, CD8 Qd655 (Invitrogen); CD16 Ax594, CD20 Ax700PE, CD56 Cy5PE, Perforin Ax680 (in-house conjugates, BD Biosciences). Cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) for intracellular cytokine detection and fixed with 1% formaldehyde (Tousimis).
To evaluate cellular exhaustion, cryopreserved PBMCs were stimulated for 6 h at 37 uC with SIV Gag/Env/Pol peptide pool (2 mg ml
) in the presence of brefeldin A (10 mg ml
). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain (Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD95 Cy5PE, IFN-c FITC, TNF APC, Bcl-2 PE (BD Biosciences); CD28 ECD (Beckman Coulter); ICOS Pacific Blue (Biolegend); CD4 Qd605, CD8 Qd655, Streptavidin Cy7PE (Invitrogen); PD-1 biotinylated (R&D Systems). Cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) for intracellular cytokine detection and fixed with 1% formaldehyde (Tousimis). Transmitted/founder variant characterization. The number of transmitted/ founder variants were characterized blindly, as previously described 28 , and deposited in GenBank under accession numbers KJ201031 to KJ201503. Determination of susceptibility of circulating SIV to IFN-a. Freshly isolated, CD8-depleted PBMCs from naive rhesus macaque donors were stimulated for 3 days with 5 mg ml 21 PHA and 100 U ml 21 IL-2 in RPMI supplemented with 10% FBS, 2 mM L-glutamine, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin (RPMIComplete). Target cells were re-suspended at 10 6 cells ml 21 in RPMI-Complete containing various concentrations of recombinant human IFN-a (PBL Interferon Source) and incubated at 37 uC for 4 h. IFN-a-containing culture supernatants were collected and stored at 37 uC. Target cells were split into duplicate cultures and spinoculated for 2 h at 800g with diluted, equivalent input amounts of SIV from plasma from 14 to 18 d.p.i. from IFN-a2a or placebo macaques. Cells were washed and re-suspended in matched, stored IFN-a containing supernatants supplemented with 100 U ml 21 IL-2. After incubation at 37 uC for 7 days, cell-free culture supernatants were collected and a SIV p27 antigen capture assay was used to detect the presence of viral p27 antigen according to the manufacturer's instructions (ABL). Binding and neutralizing antibody assays. IFN-binding antibodies were assessed as previously described 31 . To evaluate for neutralizing antibodies, A549 cells (American Type Culture Collection, Manassas, VA) were seeded at 1 3 10 4 per well in RPMI with 2% FBS and 2 mM L-glutamine and incubated for 24 h. For the standard curve, IFNa2b (Hoffman La Roche, Nutley, NJ) was added to cells in twofold serial dilution from 5 IU ml 21 to 0.04 IU ml
. For measurement of IFN-a2b-neutralizing antibodies in plasma, IFN-a2b was added at a concentration of 0.5 IU ml 21 along with 160-fold diluted plasma. Control wells received medium only or 5 IU ml 21 IFN-a2b and 13.1 mg ml 21 of a control neutralizing antibody. After an additional 24 h, the media was removed and replaced with RPMI 1640 containing 2% FBS, 2 mM L-glutamine containing encephalomyocarditis virus (EMCV, American Type Culture Collection, Manassas, VA) at a multiplicity of infection of 0.5. Cells were stained with crystal violet at 52 h and assessed for cytopathic effect as measured by optical density at 570 nm. Quantitative RT-PCR. RNA was extracted from PBMCs preserved in TRIzol (Life Technologies) or from thawed cryopreserved PBMCs by RNAzol RT (Molecular Research Center, Inc.) according to the manufacturers' instructions. Purified RNA was added directly to a one-step quantitative RT-PCR reaction containing iScript RT-iTaq Taq enzyme mix (BioRad). MX1, OAS2 and b2 microglobulin were labelled with a 59 FAM reporter and 39 BHQ1 quencher (Biosearch Technologies). We used the following oligonucleotide sequences: MX1 F AGGAGTTGCCCTTCCCAGA, MX1 R CCTCTGAAGCATCCGAAATC, MX1 P TGACCAGATGCCCGCTGGT G; OAS2 F CAGTCCTGGTGAGTTTGCAGT, OAS2 R CAGCGAGGGTAAATCC TTGA, OAS2 P GCACTGGCATCAACAGTGCCAGA.
MX1 and OAS2 forward and reverse primers were used at 500 nM, and probes at 200 nM. Samples were run on an Applied Biosystems Sequence Detection System 7900HT (ABI). Expression levels of MX1 and OAS2 were normalized to b2 microglobulin and calculated based on the DDCT method. Transcriptome analysis. Total RNA was prepared as described above. Polyadenylated transcripts were purified on oligo-dT magnetic beads, fragmented, reverse transcribed using random hexamers and incorporated into barcoded cDNA libraries based on the Illumina TruSeq platform. Libraries were validated by microelectrophoresis, quan- 
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RNA-seq data generated using the v.4 assembly demonstrated a greater absolute number of mapping reads, higher proportion of mapped reads per sample than to the hg19 RefSeq or RheMac2 assembly (Supplementary Fig. 1 and Supplementary Information). RNA-seq data analysis. RNA-seq data were submitted to The Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (NCBI). RNA-seq data were aligned to a provisional assembly of Indian Macaca mulatta (MuSuRCA rhesus assembly v.4) using STAR version 2.3.0e 32 ; parameters were set using the annotation as a splice junction reference, un-annotated noncanonical splice junction mappings and non-unique mappings were removed from downstream analysis. Transcripts were annotated using the provisional UNMC annotation v4.12. Transcript assembly, abundance estimates and differential expression analysis were performed using Cufflinks v2.1.1 and Cuffdiff
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. Samples with ,49% mapped reads or exhibiting considerable 39 or 59 bias were excluded from further analysis. To reduce normalization bias due to varying read depths, samples were analysed in two separate groups: group 1 comprised 166 samples and contained the samples from PBMCs from the placebo1SIV, IFN-1ant1SIV, and pegylated IFNa2a-treated1SIV animals, and from samples for the analysis of PBMCs, LN CD4 T cells and rectal biopsies of uninfected, IFN-a2a-treated animals; the average number of mapped reads was 12,188,890 (range: 3,237,374-87,371,564). Group 2 comprised the lymph node CD4 T cells from the three SIV-infected groups consisting of 37 samples; the average mapped read count for this group was 4,898,448 (range: 1, 173, 310, 483) . Differentially expressed genes were defined by pair-wise comparison of each time point to the Day 0 baseline. We included genes that had any acute time point (0 vs 7, 10, 21, 28) that was significantly differentially expressed by a fixed discovery rate-corrected P value (q value) , 0.05. Differential gene lists were uploaded to Ingenuity Pathway Analysis software (v1.0 Ingenuity Systems, http:// www.ingenuity.com/) and pathways with significant enrichment by Fisher's exact test and the Benjamini-Hochberg multiple testing correction were identified. Heat maps and other visualization were generated using Partek Genomics Suite v6.6. Gene-set enrichment analysis (GSEA). GSEA was performed using the desktop module available from the Broad Institute (http://www.broadinstitute.org/gsea/). FPKMs for samples from the IFN-a2a and placebo groups at 7 d.p.i. were pre-filtered to remove transcripts with insufficient read coverage, and then were ranked using the signal-to-noise statistic. The gene-set was comprised of genes determined to be upregulated in unstimulated FOXO3 2/2 macrophages relative to macrophages from control mice 25 . Significance was estimated using gene-set permutation. SIV in situ hybridization, immunohistochemistry and quantitative image analysis. SIV in situ hybridization was performed as previously described 34 . Immunohistochemistry for rabbit polyclonal anti-APOBEC3G (Prestige Antibodies Powered by Atlas Antibodies HPA001812; Sigma-Aldrich), TRIM5a (Prestige Antibodies Powered by Atlas Antibodies HPA023422; Sigma-Aldrich) and MX2 (Prestige Antibodies Powered by Atlas Antibodies HPA030235; Sigma-Aldrich) were performed using a biotin-free polymer approach (Rabbit Polink-2, Golden Bridge International, Inc.) on 5 mm tissue sections mounted on glass slides, which were dewaxed and rehydrated with double-distilled H 2 O. Antigen retrieval was performed by heating sections in 0.01% citraconic anhydride containing 0.05% Tween-20 in a pressure cooker set at 122 uC for 30 s. Slides were rinsed in ddH 2 O, incubated with blocking buffer (TBS containing 0.25% casein) and incubated with diluted rabbit anti-APOBEC3G, rabbit anti-TRIM5a or rabbit anti-MX2 in blocking buffer overnight at 4 uC. Tissue sections were rinsed in wash buffer (1 3 TBS containing 0.05% Tween-20) for 10 min followed by an endogenous peroxidase blocking step using 1.5% (v/v) H 2 O 2 in TBS (pH 7.4) for 10 min and placed in wash buffer. Slides were incubated with rabbit Polink-2 HRP polymer-staining system (Golden Bridge International, Inc.) according to manufacturer's recommendations (20-30 min at room temperature) then rinsed in wash buffer. Tissue sections were developed with Impact 3,39-diaminobenzidine (Vector Laboratories), counterstained with haematoxylin and mounted in Permount (Fisher Scientific). All stained slides were scanned at high magnification (3 200) using the ScanScope CS System (Aperio Technologies, Inc.) yielding high-resolution digital scans of the entire tissue section. Regions of interest of defined area (ROIs; 500 mm 2 ) were saved on the digital image using the Aperio rectangle tool (representing nearly the entire lymph node section) and highresolution images were extracted from the ROIs of each whole-tissue scan. The per cent area of the lymph node (all anatomical compartments were included) that stained for APOBEC3G, TRIM5a and MX2 were quantified under blind analysis using Photoshop CS5 and Fovea tools. Statistical methods. Based on our previous data of rhesus macaques with acute SIV infection, the standard deviation for SIV RNA levels is 0.5 3 10 6 copies ml
21
. Using this value, 6 macaques in the IFN-1ant or IFN-a2a group and 9 macaques in the placebo group would give us 80% power to detect a 0. 8 ) at day 0 and followed until developing end-stage AIDS. Nine macaques were treated with 4 weeks of placebo saline intramuscularly starting at day 0 and challenged intrarectally with SIV MAC251 at day 0 and followed. Six macaques were injected weekly with IFN-a2a starting 1 week before the first challenge and through 4 w.p.i. Macaques required 2, 3 or 5 challenges to acquire systemic infection. Thus, macaques received 6, 7 or 9 doses of IFN-a2a. Macaques were necropsied at 12 w.p.i. per protocol. Mann-Whitney U test. f, g, Plasma SIV RNA levels at 12 w.p.i. (f) or at peak (g) stratified by the day that MX1 or OAS2 expression peaked in PBMCs in IFN-1ant (n 5 6) and placebo (n 5 9) macaques. VL, viral load. P values were calculated by Mann-Whitney U test. h, SIV gag levels in PBMCs stratified by the day that MX1 or OAS2 expression peaked in PBMCs in IFN-1ant (n 5 6) and placebo (n 5 6) macaques. P values were calculated by Mann-Whitney U test. For all panels, IFN-1ant-treated macaques are represented in red, placebo-treated macaques in blue. LETTER RESEARCH
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